ClinicalTrials.gg
RecruitingNCT06272799ATDUpdated Sep 19, 2024

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

An observational study in Breast Cancer, sponsored by Regina Elena Cancer Institute. Recruiting at 1 site in Italy. Open to female participants. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Regina Elena Cancer Institute · Observational

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
160
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Neoplasms by Regina Elena Cancer Institute — 7 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Regina Elena Cancer Institute.

Planned enrollment
5th of 11
160 · median 134
Started
2022
with 4 others
Observational
12 of 15
7 open now
Registered
13th of 15
by date

Among the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2022, is one of 12 observational ones, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, or all of them as a file.
02

Study summary

Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

Read the detailed description

Patients affected by will be included in the study and analyzed HER2 positive breast cancer with residual invasive disease after neoadjuvant chemotherapy, treated consecutively with adjuvant T-DM1 at the various Italian oncology centers.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HER2 positive breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of positive breast cancer;
  • Presence of invasive residual disease on T or N after chemotherapy including anti-HER2 agents
  • Treatment with T-DM1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. Complementary radiotherapy will be allowed as per lines guide;
  • Availability of adequate information regarding treatment with adjuvant T-DM1 in accordance with the objectives of the study;
  • Written for the prospective part and, if possible, for the recruited patients retrospectively

Exclusion criteria

Exclusion Criteria:

  • Concomitant treatments with other biological agents;
  • Absence of clinical data that allow the correct analysis of the primary and secondary objectives;
  • Patients with a history of other malignant neoplasms;
  • to the use of T-DM
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective cohort

    80 patients will form the retrospective cohort, considering consecutively all patients treated according to clinical practice outside of studies randomized

    Drug: T-DM1 adjuvant

  • Prospectively cohort

    Additional 80 patients who meet the inclusion criteria will be enrolled prospectively

    Drug: T-DM1 adjuvant

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the tolerability.

    Evaluate the tolerability of the treatment in terms of adverse events, defined according to Common Terminology Criteria for Adverse Events (CTCAE, version 4), in a population of patients treated with adjuvant T-DM1 in "real life"

    Time frame: 24 months

Secondary outcomes

  1. Evaluate the effectiveness of treatment.

    Evaluate in the "real life setting" the effectiveness of adjuvant treatment in terms of survival free from disease (Disease Free Survival, DFS) in patients with HER2 positive breast cancer and residual invasive disease (on T and/or on N) after neoadjuvant chemotherapy.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • "Regina Elena" National Cancer Institute
    Rome, 00144, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 22, 2024
StartActual
Sep 20, 2022
Primary completionEst.
Sep 20, 2024
CompletionEst.
Sep 20, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06272799
Lead sponsor
Regina Elena Cancer Institute
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Sep 20, 2022
Primary completion
Sep 20, 2024 (estimated)
Completion
Sep 20, 2024 (estimated)
Last update
Sep 19, 2024

Study contacts

Patrizia Vici, Doctor
Contact
patrizia.vici@ifo.it
+39 06-5266.5698 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion